GOP lawmaker: Democrats’ tech proposals will include ‘non-starters for conservatives’

Buck said he opposes not-yet-unveiled Democratic proposals aimed at “eliminating arbitration clauses and further opening companies up to class action lawsuits.” And he said he rejects antitrust subcommittee Chair David Cicilline’s (D-R.I.) idea of advancing legislation to force structural breakups of major online platforms like Amazon.

“We agree that antitrust enforcement agencies need additional resources and tools to provide proper oversight,” Buck wrote. “However, these potential changes need not be dramatic to be effective.”

The Republican recommendations mark the first major findings to surface out of the Judiciary Committee’s probe. Though the subcommittee’s final report has yet to be released, Democrats have floated sweeping changes such as legislation to force structural separations for tech platforms similar to Glass-Steagall, the Depression-era law that split investment and retail banking.

In the memo, Buck wrote that the majority’s incoming report “offers a chilling look into how Apple, Amazon, Google, and Facebook have used

Read More

Trump administration proposals could stymie personalized medicine

“It is more important to know what kind of patient the disease has than to know what kind of disease the patient has.”

Although Hippocrates made this keen observation more than 2,400 years ago, physicians did not have the tools to decipher the biological and environmental factors influencing an individual’s health and well-being until recently.

Since the human genome was finally mapped in 2003, scientists have made tremendous progress in advancing personalized medicine. By tailoring health care to an individual’s biological characteristics, circumstances, and values, personalized medicine can bring unprecedented benefits to patients with rare genetic disorders, cancer, and other diseases.

advertisement

The widely variable effects of the novel coronavirus serve as a painful reminder of the importance of understanding how and why people respond differently to the same disease.

But two recent moves by the Trump administration threaten to turn back the clock on biomedical progress in personalized

Read More